Raffa Wealth Management’s Myriad Genetics MYGN Stock Holding History

Raffa Wealth Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-7,600	Closed	-$233K	–	882
2016 Q2	$233K	Hold	7,600	–	–	0.13%	51
2016 Q1	$284K	Hold	7,600	–	–	0.16%	45
2015 Q4	$328K	Hold	7,600	–	–	0.2%	33
2015 Q3	$285K	Buy	7,600 +250	+3%	+$8.87K	0.17%	35
2015 Q2	$250K	Buy	7,350 +150	+2%	+$5.1K	0.15%	43
2015 Q1	$255K	Sell	7,200 -4,350	-38%	-$156K	0.15%	40
2014 Q4	$393K	Buy	11,550 +160	+1%	+$5.68K	0.24%	29
2014 Q3	$439K	Buy	11,390 +140	+1%	+$5.22K	0.33%	21
2014 Q2	$438K	Buy	11,250 +112	+1%	+$4.17K	0.33%	21
2014 Q1	$381K	Sell	11,138 -412	-4%	-$12.8K	0.31%	27
2013 Q4	$393K	Buy	+11,550	New	+$292K	0.24%	29

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Raffa Wealth Management's MYGN Position: Q3 2016 in Review

Raffa Wealth Management sold out of Myriad Genetics (MYGN) in Q3 2016, closing a stake of 7,600 shares — an estimated $233K sold.

Raffa Wealth Management first reported a position in MYGN in Q4 2013 and held it in 11 quarters. The position peaked at $439K in Q3 2014. 223 funds tracked by Wall St. Rank hold MYGN as of Q3 2016.

Raffa Wealth Management reported no remaining Myriad Genetics position as of Q3 2016 after selling out during the quarter.
Raffa Wealth Management sold 7,600 Myriad Genetics shares in Q3 2016, an estimated $233K.
Raffa Wealth Management first reported a position in Myriad Genetics in Q4 2013 and held it in 11 quarters.
Raffa Wealth Management's Myriad Genetics position peaked at $439K in Q3 2014.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2016.

Based on Raffa Wealth Management's 13F filing for Q3 2016, filed 27 Jul 2026.